ClinicalTrials.gg
Active, not recruitingNCT06647745THP-001-031Updated Nov 9, 2026

A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension

A Phase 3 interventional study of THP-00101 and THP-00102 in Type 2 Diabetes and Hypertension, sponsored by THPharm Corp.. Active, not recruiting at 2 sites in 2 countries. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by THPharm Corp. · Phase 3, Interventional, and Treatment

How we know

Updated Nov 9, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
222
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of — 70 open to participants now, 84 under way, 26 of them phase 3. Diabetes Mellitus, Type 2 · Korea, Republic of.

Enrollment
215th of 493
222 · median 174
Started
2025
with 20 others
Phase 3
200 of 571
22 open now
Primary completion
2026-11
later than 37 of 83 live
Registered
501st of 571
by date

Among the 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of, this one is the 215th largest by enrollment of the 493 interventional ones that give a count, is one of 21 that started in 2025, is one of 200 in phase 3, reaches primary completion later than 37 of the 83 other live ones, and was the 501st registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

70 of the 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of, or all of them as a file.
02

Study summary

[Primary Objective] To demonstrate the superiority of the change in mean sitting systolic blood pressure (MSSBP) and hemoglobin A1c (HbA1c)on week 12 of the combination therapy of THP-00101 (dapagliflozin 10 mg) and THP-00102 (telmisartan 80 mg) compared to THP-00101 or THP-00102 monotherapy among subjects with type 2 diabetes mellitus accompanied by essential hypertension. [Secondary Objective] To comparatively evaluate secondary efficacy and safety in the THP-00101 monotherapy group, THP-00102 monotherapy group, THP-00101 and THP-00102 combination therapy group, and THP-00101 and THP-00103 (telmisartan 40 mg) combination therapy group among subjects with type 2 diabetes mellitus accompanied by essential hypertension.

03

Conditions studied

  • Type 2 Diabetes
  • Hypertension
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Screening (V1)

    1. Adult males and females aged 19 (the legal adult age of each country) and above on the date of written
    2. Subjects with type 2 diabetes mellitus accompanied by essential hypertension
    3. Subjects with the following (HbA1c) and fasting plasma glucose (FPG) levels at screening (V1)*
  • hemoglobin A1c less than or equal to 9.5% and more than 6.5%
  • fasting plasma glucose less than or equal to 270 mg/dL

    • Including subjects who did not use oral hypoglycemic agents within 8 weeks from screening and subjects who took metformin monotherapy or dual combination therapy that included metformin for 8 weeks or longer from screening 4. Subjects with the following mean sitting systolic blood pressure (MSSBP) measured in the reference arm** at screening (V1)***
  • If not taking antihypertensive agents: MSSBP less than 160 mmHg and more than 140 mmHg
  • If taking antihypertensive agents: MSSBP less than 160 mmHg and more than 130 mmHg **Reference arm: The arm with the higher MSSBP after measuring it 3 times in each arm at screening (V1) (If the MSSBP is the same between both arms, then the arm with the higher mean sitting diastolic blood pressure (MSDBP) is selected as the reference arm.)

    ***Classified based on whether antihypertensive agents were administered within 4 weeks from screening (V1) 5 Subjects considered by the investigator appropriate to discontinue the use of oral hypoglycemic agents and antihypertensive agents, other than the existing metformin, during the study (with metformin maintained at a minimum of 1,000 mg/day) 6 Subjects who received a sufficient explanation of the objectives and content of the study and voluntarily provided written informed consent

  • Baseline (V2)

    1. Subjects with the following HbA1c and FPG levels at baseline (V2) - HbA1c less than or equal to 9.5% and more than 6.5% - FPG less than or equal to 270 mg/dL 2. Subjects with the following MSSBP measured in the reference arm at baseline (V2) - MSSBP less than 160 mmHg and more than 140 mmHg 3. Subjects who did not take oral hypoglycemic agents other than the same dose of metformin (More than 1,000 mg/day) for at least 8 weeks before baseline (V2) 4. Subjects who did not take antihypertensive agents for at least 2 weeks before baseline (V2) 5. Subjects with no disqualifying inclusion/exclusion criteria of screening (V1) when evaluating eligibility again at baseline (V2) 6. Subjects with compliance of 70% or higher with the product during the run-in period

  • Extension Period

    1. Subjects who have completed all procedures of the treatment period. Subjects who are unsuitable to participate in the study of the extension period, considering safety, etc., can be excluded.
    2. Subjects who received a sufficient explanation of the objectives and content of the extension period study and voluntarily provided written informed consent

Exclusion criteria

Exclusion Criteria:

1. Subjects with the following blood pressures measured at screening (V1) and randomization (V2)

(1) Subjects with the following MSDBP measured in the reference arm

  • MSDBP ≥110 mmHg (2) Subjects with the following difference in mean blood pressure measured three times consecutively in each arm at least 2 minutes apart at screening (V1): MSSBP ≥20 mmHg and MSDBP ≥10 mmHg 2. Subjects with a of >35 kg/m2 3. Subjects with the following comorbidities or conditions

    1. Mild to severe hepatic impairment
    2. Biliary obstruction or cholestasis
    3. or ALT ≥2 x
    4. Total >2 x ULN
    5. Patients with moderate (stage 3b) or severe renal impairment ( by IDMS-MDRD \<45 mL/min/1.73 m2)
    6. Acute conditions that may affect renal function, such as dehydration, severe infection, cardiovascular collapse (shock), and sepsis
    7. Diabetic precoma and coma
    8. Severe infection or severe traumatism
    9. Malnutrition, starvation, debilitation, pituitary insufficiency, or adrenal dysfunction
    10. Acute or chronic diseases that may cause tissue hypoxia such as respiratory failure (pulmonary infarction and severe pulmonary dysfunction) and shock, and gastrointestinal disorders including dehydration, diarrhea, and vomiting
    11. Orthostatic hypotension with symptoms
    12. ventricular tachycardia, atrial fibrillation, atrial flutter, or other arrhythmia considered clinically significant as judged by the investigator
    13. Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically significant aortic valve or mitral valve stenosis
    14. Wasting diseases, diseases, and connective tissue diseases
    15. Dysuria, anuria, oliguria, and ischuria that cannot be controlled by drugs
    16. Gastrointestinal diseases that may affect the absorption of the product (gastrointestinal ulcer, gastritis, gastric spasm, gastroesophageal reflux disease, Crohn's disease, etc.)
    17. Subjects who are positive§ or antibody positive∥

      §Subjects who are taking antiviral products stably may participate

      ∥Subjects with negative HCV RNA test results may participate

    18. Subjects who are positive for Ag/Ab combo test 4. Subjects with the following past medical history

    <!-- -->

    1. Hereditary angioedema or angioedema caused by ACE inhibitor or angiotensin II antagonist treatment.
    2. Hereditary problems such as galactose intolerance, Lapp lactose deficiency, glucose-galactose malabsorption, etc.
    3. Type 1 diabetes mellitus, secondary diabetes mellitus, lactic acidosis, acute or chronic metabolic acidosis, and ketoacidosis including diabetic ketoacidosis accompanied or not accompanied by coma
    4. Drug abuse or alcohol abuse
    5. Past medical history of secondary hypertension or all medical history suspected of secondary hypertension (not limited to the following: coarctation of aorta, primary hyperaldosteronism, renal artery stenosis, Cushing's syndrome, pheochromocytoma, polycystic kidney disease, etc.)
    6. Severe cardiac failure ( class III and IV), ischemic heart disease (unstable angina and myocardial infarction), and peripheral vascular diseases that occurred within 24 weeks before screening (V1)
    7. Severe cerebrovascular diseases (stroke, cerebral infarction, cerebral hemorrhage, etc.) that occurred within 24 weeks before screening (V1)
    8. Moderate or malignant retinopathy that occurred within 24 weeks before screening (V1) (retinal hemorrhage, visual disturbance, and retinal microaneurysm that occurred within the last 24 weeks)
    9. Urinary tract infection or genital infection that occurred within 16 weeks before screening (V1)
    10. Malignant tumors that occurred within the last 5 years. Subjects who experienced no recurrence for at least 5 years after being declared cured or in the cases of basal cell carcinoma, squamous cell carcinoma of the skin, thyroid cancer, or carcinoma in situ at other sites, subjects who experienced no recurrence for at least 3 years after being declared cured can be enrolled based on the investigator's medical judgment 5. Subjects who received the following medication or non-pharmacological therapy at screening (V1)

    <!-- -->

    1. Bariatric surgery or lap-band surgery within 12 months before screening (V1)
    2. Percutaneous transluminal coronary angioplasty or coronary artery bypass graft surgery within 24 weeks before screening (V1)
    3. Antiobestic drugs or drugs based on the investigator's judgment to be capable of having significant effects on weight control within 12 weeks before screening (V1)
    4. Systemic used for 2 weeks or longer, within 8 weeks before screening (V1) (inhaled and topical agents, eye drops, intranasal, intra-articular administration, and other localized administrations are allowed regardless of duration)
    5. Insulin injections or GLP-1 receptor agonists administered for more than 7 days consecutively or non-consecutively within 8 weeks before screening (V1)
    6. Current treatment by the triple combination of antihypertensive agents, or current treatment by the dual combination including high-dose amlodipine (10 mg)
    7. Current treatment by the monotherapy of hypoglycemic agents except metfomin or current treatment by the triple combination including metformin
    8. Current treatment with drugs containing aliskiren
    9. Subjects currently receiving dialysis
    10. Scheduled tests involving the intravenous administration of radiographic iodinated contrast agents from 48 hours before the run-in period until the end of the study (e.g., intravenous urography, intravenous angiography, vascular angiography, computed tomography using contrast agents, etc.) 6. Subjects who are hypersensitive to the active ingredients (dapagliflozin or telmisartan) or other ingredients of the investigational product 7. Subjects with a history of to metformin or biguanides 8. Subjects who participated in other clinical trials within 12 weeks before taking the investigational product of this study and were administered (or received) other investigational products (or devices) 9. Pregnant or breastfeeding women 10. Women and men of who have plans for pregnancy or do not agree to perform appropriate from screening (V1) until 4 weeks after the last dose of the investigational product. The appropriate contraceptive methods for this study are as follows:

    <!-- -->

    1. Hormonal contraceptives (oral products, injections, implants, etc.)
    2. IUD or IUS
    3. Male or female sterilization (e.g., vasectomy, hysterectomy, bilateral oophorectomy, bilateral salpingectomy, etc.)
    4. Dual methods: Simultaneous use of 1) to 3) methods and the barrier method¶ or simultaneous use of double barrier methods# (simultaneous use of cap/diaphragm and male condom) and the spermicide
    5. Sexual abstinence: It is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. However, if the age, job, lifestyle, or sexual orientation of the participant assures contraception according to the investigator's decision, strict abstinence from sexual intercourse is also allowed. Periodic sexual abstinence (e.g., calendar method, symptothermal method, post-ovulation method, etc.) and withdrawal (coitus interruptus) are not acceptable methods of contraception.

      • Male condom, female condom, cap, diaphragm, sponge, etc. #However, simultaneous use of male condoms and female condoms is not allowed 11. Subjects unsuitable to participate in this study based on the investigator's judgment.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
222 participants (actual)

Study arms

  • Experimental
    Study group

    The participant will receive the investigational drugs THP-00101 (Dapagliflozin 10 mg), THP-00102 (Telmisartan 80 mg), and a placebo for THP-00103 once a day by per oral over 12 weeks

    Drug: THP-00101 · Drug: THP-00102 · Drug: THP-00106

  • Placebo comparator
    Control group 1

    The participant will receive the investigational drugs THP-00101 (Dapagliflozin 10 mg), Placebo of THP-00102, and Placebo of THP-00103 once a day by per oral over 12 weeks

    Drug: THP-00101 · Drug: THP-00104 · Drug: THP-00105

  • Placebo comparator
    Control group 2

    The participant will receive the investigational drugs Placebo of THP-00101, THP-00102 (Telmisartan 80 mg), and Placebo of THP-00103 once a day by per oral over 12 weeks

    Drug: THP-00102 · Drug: THP-00104 · Drug: THP-00106

  • Other
    Exploratory group

    The participant will receive the investigational drugs THP-00101 (Dapagliflozin 10 mg), Placebo of THP-00102, and THP-00103 (Telmisartan 40 mg) once a day by per oral over 12 weeks

    Drug: THP-00101 · Drug: THP-00103 · Drug: THP-00105

Interventions

  • DrugTHP-00101

    Dapagliflozin 10 mg

    Also known as: Forxiga Tab. 10mg

  • DrugTHP-00102

    Telmisartan 80 mg

    Also known as: Micardis Tab. 80mg

  • DrugTHP-00103

    Telmisartan 40 mg

    Also known as: Micardis Tab. 40mg

  • DrugTHP-00104

    Placebo of Dapagliflozin 10mg

    Also known as: Placebo of Fociga Tab. 10mg

  • DrugTHP-00105

    Placebo of Telmisartan 80mg

    Also known as: Placebo of Micardis Tab. 80mg

  • DrugTHP-00106

    Placebo of Telmisartan 40mg

    Also known as: Placebo of Micardis Tab. 40mg

06

What researchers measure

Primary outcomes

  1. Changes in Hemoglobin A1c (HbA1c)

    The Hemoglobin A1c will be measured using the high-performance liquid chromatography (HPLC) method.

    Time frame: 12 weeks

  2. Changes in Mean Sitting Systolic Blood Pressure (MSSBP)

    When using a digital blood pressure monitor, the subject should sit on a chair with their back supported, relax for at least 5 minutes, and keep their arm at heart level during the measurement

    Time frame: 12 Weeks

Secondary outcomes

  1. Changes in glycemic parameter: hemoglobin A1c

    HbA1c will be measured

    Time frame: 4, 8, and 12 weeks from baseline

  2. Changes in glycemic parameter: fasting plasma glucose

    FPG will be measured

    Time frame: 4, 8, and 12 weeks from baseline

  3. Changes in glycemic parameter: homeostasis model assessment of insulin resistance (HOMA-IR)

    HOMA-IR will be measured using high-performance liquid chromatography and the hexokinase method.

    Time frame: 4, 8, and 12 weeks from baseline

  4. Changes in glycemic parameter: homeostasis model assessment of beta-cell function (HOMA-beta)

    HOMA-beta will be measured using high-performance liquid chromatography and the hexokinase method

    Time frame: 4, 8, and 12 weeks from baseline

  5. Changes in blood pressure: mean sitting systolic blood pressure

    When using a digital blood pressure monitor, the subject should sit on a chair with their back supported, relax for at least 5 minutes, and keep their arm at heart level during the measurement

    Time frame: 4, 8, and 12 weeks from baseline

  6. Changes in blood pressure: mean sitting diastolic blood pressure

    When using a digital blood pressure monitor, the subject should sit on a chair with their back supported, relax for at least 5 minutes, and keep their arm at heart level during the measurement

    Time frame: 4, 8, and 12 weeks from baseline

  7. Changes in blood pressure: pulse pressure

    When using a digital blood pressure monitor, the subject should sit on a chair with their back supported, relax for at least 5 minutes, and keep their arm at heart level during the measurement

    Time frame: 4, 8, and 12 weeks from baseline

  8. Changes in blood pressure: percentage of normalized blood pressure

    When using a digital blood pressure monitor, the subject should sit on a chair with their back supported, relax for at least 5 minutes, and keep their arm at heart level during the measurement

    Time frame: 4, 8, and 12 weeks from baseline

  9. Changes in blood pressure: response rate of blood pressure

    When using a digital blood pressure monitor, the subject should sit on a chair with their back supported, relax for at least 5 minutes, and keep their arm at heart level during the measurement

    Time frame: 4, 8, and 12 weeks from baseline

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Nov 2026, 18 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Jun 2026 → Nov 2026 and completion Dec 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2024
First posted
Oct 18, 2024
StartActual
Apr 10, 2025
Primary completionActual
Nov 4, 2026was Jun 2026
CompletionEst.
Jan 28, 2027was Dec 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 9, 2026
Primary completion
Jun 1, 2026→Nov 4, 2026 (actual)
Nov 9, 2026
Study completion
Dec 1, 2026→Jan 28, 2027
Nov 9, 2026
Enrollment
221 (estimated)→222 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Recruiting→Active, not recruiting
    Primary completion Jun 1, 2026→Nov 4, 2026 (now actual)
    Study completion Dec 1, 2026→Jan 28, 2027
    Enrollment 221 (estimated)→222 (actual)
    + 4 other changes: verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06647745
Lead sponsor
THPharm Corp.
Responsible party
Sponsor
First posted
Oct 18, 2024
Start date
Apr 10, 2025
Primary completion
Nov 4, 2026
Completion
Jan 28, 2027 (estimated)
Last update
Nov 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion